Glial toxicity in urine and multiple sclerosis

Multiple Sclerosis

Volumn 7, Issue 6, 2001, Pages 383-388

  Malcus Vocanson, C ^a   Giraud, P ^a   Micoud, F ^a   Janin, V ^a   Charles, M H ^a   Broussolle, E ^a   Chazot, G ^a   Mandrand, B ^a   Perron, H ^a  

^a Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Cytotoxicity; Disease marker; Glial cell; Multiple sclerosis; Urine

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTE; BIOASSAY; BIOCHEMISTRY; CELL LINE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DRUG SCREENING; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; MALE; MOLECULAR DYNAMICS; MONITORING; MONOCYTE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OLIGODENDROGLIA; STATISTICAL ANALYSIS; TARGET CELL; URINALYSIS;

ADULT; ANIMALS; APOPTOSIS; BIOLOGICAL ASSAY; CELL LINE; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; NEUROGLIA; REFERENCE VALUES; URINE;

EID: 0035214372     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245801701567104     Document Type: Article

References (25)

1. New diagnosis criteria for multiple sclerosis: Guidelines for research protocols
2. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG-index
3. Isoelectric focusing in an immobilized pH gradient for the detection of intrathecal IgG in cerebrospinal fluid: Sensitivity and specificity for the diagnosis of multiple sclerosis
4. CSF oligoclonal bands, MRI and the diagnosis of multiple sclerosis
5. Long term follow-up of multiple sclerosis by standardized, non-contrast-enhanced magnetic resonance imaging
6. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis
7. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing remitting multiple sclerosis (MS): Implications for phase II therapeutic trials
8. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course
9. The natural history of multiple sclerosis
10. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
11. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis
12. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis
13. Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease
14. Retrovirus MSRV et proteine gliotoxique: Marqueurs biologiques potentiels dans la sclérose en plaques?
15. Gliotoxicity, reverse transcriptase activity and retroviral RNA in monocyte/macrophage culture supernatants from patients with multiple sclerosis
16. Detection of a gliotoxic activity in the cerebrospinal fluid from multiple sclerosis patients
17. A urinary marker for multiple sclerosis
18. A gliotoxic factor in multiple sclerosis
19. Case report: DNA fragmentation in glial cells in a cerebral biopsy from a multiple sclerosis patient
20. Establishment of permanent astroglial cell lines, able to differentiate in vitro, from transgenic mice carrying the polyoma virus large T gene: An alternative approach to brain cell immortalization
21. Comparison of several techniques for the detection of apoptotic astrocytes in vitro
22. Flow cytometric detection of apoptosis: Comparison of the assays of in situ DNA degradation and chromatin changes
23. Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis
24. Body fluid markers to monitor multiple sclerosis: The assays and the challenges
25. Biological markers in body fluids for activity and progression in multiple sclerosis